Head and Neck Diseases by Alexandros G.Sfakianakis: Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.

Πέμπτη 19 Απριλίου 2018

Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.

https:--www.ncbi.nlm.nih.gov-corehtml-pm

Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.

Blood Cancer J. 2016 11 11;6(11):e496

Authors: Betrian S, Ysebaert L, Heider KH, Delord JP, Fournié JJ, Quillet-Mary A

PMID: 27834943 [PubMed - indexed for MEDLINE]

https://ift.tt/2HMrTY2

Head and Neck Diseases by Alexandros G.Sfakianakis

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Πέμπτη 19 Απριλίου 2018

Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου